Applicability of an absolute quantitative procedure to monitor intra‐individual bcr/abl transcript kinetics in clinical samples from chronic myelogenous leukemia patients

Chimeric bcr/abl fusion proteins are thought to be the molecular 'pathogen' of chronic myelogenous leukaemia (CML). Expression levels of the respective fusion RNAs reflect disease progression as well as remission upon therapeutic intervention in CML patients. However, there is no quick and reliable method that would allow the quantitative routine monitoring of bcr/abl hybrid transcripts. A fluorescent probe‐based PCR assay (TaqMan) has been described to quantitfy the exact amount of target sequences. We have established TaqMan real‐time RT‐PCRs for M‐bcr/abl (b2a2, b2a3, b3a2, b3a3) and m‐bcr/abl (e1a2) fusion transcripts as well as for β‐actin. All PCRs quantified as little as 10 copies/100 ng total cDNA. In order to investigate whether this procedure is appropriate for routine diagnostic monitoring, we performed retrospective measurements on 9 documented CML disease courses. Our data show that ongoing or relapsing CML is paralleled by increasing peripheral levels of bcr/abl fusion RNAs. Furthermore, sucessful anti‐leukemic treatment is reflected by decreasing absolute bcr/abl transcript numbers. In contrast with conventional bcr/abl PCR techniques we could distinguish single positive values and gradually increasing copy numbers. Int. J. Cancer 86:741–746, 2000. © 2000 Wiley‐Liss, Inc.

[1]  U. Lass,et al.  LightCycler technology for the quantitation of bcr/abl fusion transcripts. , 1999, Cancer research.

[2]  D. Huhn,et al.  Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of beta-actin transcripts as quantitative reference. , 1999, Clinical chemistry.

[3]  J. Klein,et al.  Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia , 1997, British journal of haematology.

[4]  P. Houillier,et al.  Cytokines-related hypercalcaemia associated with haematological malignancy. , 1997, British journal of haematology.

[5]  S. Ralston,et al.  Control genes for reverse-transcription-polymerase chain reaction: a comparison of beta actin and glyceraldehyde phosphate dehydrogenase. , 1997, British journal of haematology.

[6]  C. Bloomfield,et al.  Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Melo,et al.  Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results. , 1996, Leukemia.

[8]  Melo Jv.  The molecular biology of chronic myeloid leukaemia. , 1996 .

[9]  C. Preudhomme,et al.  Frequency of molecular elimination of Ph1 clone in chronic myelogenous leukemia (CML) with interferon alpha. , 1996, Leukemia.

[10]  K. Livak,et al.  Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. , 1995, PCR methods and applications.

[11]  H. Kantarjian,et al.  Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. , 1995, Blood.

[12]  J. Radich,et al.  Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. , 1995, Blood.

[13]  A. Chase,et al.  Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. , 1993, Blood.

[14]  H. Kantarjian,et al.  Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation , 1992, British journal of haematology.

[15]  J. Wang,et al.  Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. , 1991, Cancer research.

[16]  O. Witte,et al.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias , 1991, Molecular and cellular biology.

[17]  M. Pondel.  BCR First ExonSequences Specifically Activate theBCRIABL Tyrosine Kinase Oncogene ofPhiladelphia Chromosome- Positive HumanLeukemias , 1991 .

[18]  R. Kurzrock,et al.  Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression. , 1991, Leukemia.

[19]  P. Martiat,et al.  Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers , 1990, British journal of haematology.

[20]  P. Martiat,et al.  False-positive results with PCR to detect leukaemia-specific transcript , 1990, The Lancet.

[21]  M. Vidaud,et al.  Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia. , 1990, Leukemia.

[22]  J. Gabert,et al.  DETECTION OF RESIDUAL bcr/abl TRANSLOCATION BY POLYMERASE CHAIN REACTION IN CHRONIC MYELOID LEUKAEMIA PATIENTS AFTER BONE-MARROW TRANSPLANTATION , 1989, The Lancet.

[23]  D. Ginsburg,et al.  Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia , 1989 .

[24]  W. Lange,et al.  Detection by enzymatic amplification of bcr-abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia. , 1989, Blood.

[25]  E. Canaani,et al.  Molecular biology of chronic myelogenous leukemia. , 1988, Seminars in hematology.

[26]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[27]  A. Berrebi,et al.  bcr-abl RNA in patients with chronic myelogenous leukemia. , 1987, Blood.

[28]  R. Gale,et al.  THE MOLECULAR BIOLOGY OF CHRONIC MYELOGENOUS LEUKAEMIA , 1985, British journal of haematology.

[29]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[30]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .